Schlieren, Switzerland – February 16, 2022 – Memo Therapeutics AG ("MTx"), an innovator in the field of antibody discovery and development, announced today the close of an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination of strategic and financial investors, including Adjuvant Capital, Fresenius Medical Care Ventures, GF Group, Verve Ventures, Vesalius Biocapital and Zürcher Kantonalbank.

Hamburg, February 15, 2022 – Topas Therapeutics GmbH (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced the appointment of Cristina de Min, M.D., as Chief Medical Officer. In this position, she will be responsible for Topas' clinical development programs based on its proprietary Topas Particle Conjugates technology platform.

22 November 2021, 10:00 WET – Sword Health, a provider of virtual and digital physical therapy, is valued at $2 billion after a funding round led by Sapphire Ventures that saw its valuation increase by more than 18 times since January.

JERSEY CITY, N.J. & TURKU, FINLAND – Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women's health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor in early clinical development for endometriosis, being evaluated for its potential effect on endometriotic lesions. Endometriosis is a common and chronic condition that affects up to 1 in 10 women of reproductive age, causes abdominal pain and is associated with infertility.

Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV ('Rejuvenate'), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round.

Gosselies, Belgium, September 30th, 2021 – OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, and SOPHiA GENETICS S.A., a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research, announced today an agreement facilitating the analysis and interpretation of genomic profiling.

Hamburg, July 27, 2021  – Topas Therapeutics GmbH (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced that the Company has successfully extended its Series B round with an additional €18 million (~$22 million) raised, bringing the total for this financing to €40 million.

New York, July 06, 2021 (GLOBE NEWSWIRE) – SWORD Health, the fastest growing virtual musculoskeletal care provider, today announced an $85M Series C funding round. This news follows SWORD's $25 million Series B in January, bringing the company's total to $135M in funding to-date

Amsterdam, June 6, 2021 – DEARhealth, a health tech company focused on AI-powered chronic disease management, today announced that it has obtained certification for ISO 13485 (quality management systems for medical devices) and the certificate of conformity according to the European Union Medical Device Regulation (MDR) as a class IIa medical device for the first release of the DEARhealth patient and care software.

Munich, Germany, May 4, 2021 – CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L'Huillier as Chief Executive Officer (CEO), effective May 17, 2021.